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Psoriasis is a common chronic inflammatory skin condition in which patients suffer frommild to chronic plaque skin plaques.The
disease manifests through an excessive inflammatory response in the skin due to complex interactions between different genetic
and environmental factors. Psoriasis can affect the physical, emotional, and psychosocial well-being of patients, and currently there
is no cure with treatments focusing primarily on the use of anti-inflammatory agents to control disease symptoms. Traditional
anti-inflammatory agents can cause immunosuppression and adverse systemic effects. Further understanding of the disease has led
to current areas of research aiming at the development of selective molecular targets to suppress the pathogenic immune responses.
1. Introduction
Psoriasis is an immune-mediated skin disease appearing in a
chronic recurring manner. Prevalence estimates show that it
affects 1-2% of the worldwide population with equal gender
distribution. Psoriasis can emerge at any time of life and
it usually peaks between the ages of 30–39 and 60–69 [1].
Sufferers may experience itch, pain, and/or psoriasis-related
nail disease and arthritis. Significantmorbidity extends to the
psychosocial impact on the individual. Psoriatic patients are
often stigmatised by people staring at their disfigured skin;
they may have low self-esteem and would face difficulties in
relationships and employment [2]. Psoriasis has also been
associated with an increased risk of cardiovascular diseases,
stroke and cancer, although a direct link to the latter is still
lacking [3].
Psoriasis was initially thought to be primarily a disease
of dysfunctional proliferation and differentiation of the ker-
atinocytes [4]. However, now it is widely accepted that T
helper (Th)1 and Th17 lymphocytes contribute to the disease
pathogenesis through the release of inflammatory cytokines
that promote further recruitment of immune cells, ker-
atinocyte proliferation, and sustained chronic inflammation
[4, 5]. Well-demarcated erythematous plaques covered by
white silvery scales are typically observed on extremities and
scalp of patients with psoriasis (Figures 1(a)–1(c)). Histologi-
cal assessment of psoriatic plaques demonstrates keratinocyte
hyperproliferation with parakeratosis, epidermal elongation
or rete ridges, increased angiogenesis, and dermal infiltra-
tion of inflammatory cells, including T cells, neutrophils,
macrophages, and dendritic cells (DCs) [4] (Figure 1(d)).
Other histological features often observed in psoriatic skin
include micropustules of Kogoj, microabscesses of Munro,
thinned or absent granular layer, thinned suprapapillary
plates, and the papillary dermis containing dilated superficial
vessels [4]. The aetiology of psoriasis appears to be mul-
tifactorial. Environmental triggers (such as trauma, stress,
infections, and drugs) activate, in polygenic predisposed
individuals, an exaggerated inflammatory response in the
skin [4, 5]. The principle of existing treatment strategies is
aimed at controlling the severity of the disease and preventing
relapses as complete clearance may not be achievable with
currently available agents.
2. Genetic Background
First- and second-degree relatives of psoriatic patients are
more likely to develop psoriasis than the general population,
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Figure 1: Clinical and histological appearance of stable chronic psoriatic plaques. Note the well-demarcated erythematous plaques covered
by white-silvery scales distributed on the lower back (a), extremities (b), and scalp (c). Histological appearance of the chronic psoriatic
plaque (d) reveals acanthosis (white arrow head), elongated epidermal rete ridges (two-headed arrow), and hyperkeratosis (black arrow
head). Inflammatory cells are present in the dermis (long arrow) and sometimes in the epidermis known as Munro’s microabscess which are
composed of neutrophils (short arrow).
even though segregation analyses show no clear pattern of
inheritance [4, 5]. Disease concordances are two to three
times more likely in monozygotic twins than in dizygotic
twins [4, 5]. To elucidate the genetic predisposition, several
genomewide scans have reported at least nine chromosomal
loci linked to psoriasis (psoriasis susceptibility (PSORS) 1–
9) [6]. PSORS1 accounts for 35–50% of the heritability of
the diseases but not the entire genetic predisposition [5, 6].
PSORS1 is located on the major histological complex (MHC)
region of chromosome 6 (6p21) [4–6].Three genes contained
within this region are associated with psoriasis, namely,
HLA-Cw6, CCHCR1 (coiled-coil 𝛼-helical rod protein), and
CDSN (corneodesmosin) [4, 5]. HLA-Cw6 encodes a class
I MHC protein and is associated with early-onset chronic
plaque psoriasis [4, 5]. CCHCR1 encodes coiled-coil𝛼-helical
rod protein 1 which is highly expressed in psoriatic epider-
mis and regulates keratinocyte proliferation [4, 5]. CDSN
encodes corneodesmosin, a late differentiation epidermal
glycoprotein overexpressed in the granular and cornified
layers of the epidermis involved in keratinocyte adhesion
[4, 5, 7]. PSORS2 is a replicated locus on chromosome
17q, and a polymorphism causing loss of binding to the
RUNX1 transcription factor is associated with psoriasis [4,
8]. PSORS4 is located within the epidermal differentiation
complex on chromosome 1q [4, 9]. Other susceptibility
loci have been identified which include genes expressed
in keratinocytes (LCE3B (late cornified envelope 3B) and
LCE3C1 (late cornified envelope 3C1)) and immune cells (IL-
(interleukin-) 12B, IL23R (IL-23 receptor), and IL23A), and
they are involved in maintaining epidermal skin barrier and
immune responses against pathogens [5]. Further genetic
studies on larger cohorts of patients suffering from psoriasis
are required to elucidate the exact involvement of these genes
in the pathogenesis of psoriasis.
3. Pathogenesis
Since the late 1970s, when T-cell-targeted immunosuppres-
sants were inadvertently found to be efficacious in treating
psoriasis, it was clear that T cells play a major role in the
pathogenesis of psoriasis. The most indicative evidence was
found when T-cell proliferation was blocked in different
murinemodels resulting in reduced development of psoriasis
[10].The infiltration of dermal leucocytes in psoriasis consists
predominantly of CD4+ and CD8+ T cells and may precede
epidermal hyperplasia [4, 5, 10]. The majority of activated T
cells express cutaneous lymphocyte-associated antigen which
guides T cell skin homing [11]. Although these T-cells prolif-
erate in the epidermis of psoriatic plaques, the autoantigen or
immunogen responsible has yet to be identified [12, 13]. The
primary antigen proposed to be involved is from Streptococci
bacteria due to a number of observations including psori-
asis can be exacerbated after streptococcal throat infection;
psoriasis improves with tonsillectomy; and circulating T cells
of psoriatic patients respond to streptococcal antigens with
enhanced production of IFN- (interferon-) 𝛾 [5, 13]. Since
streptococcal antigens do not appear to persist in the psoriatic
lesions, psoriasis may be initiated by T cells primed against
streptococcal proteins in the palatine tonsils [5]. It is believed
that after diapedesis into the skin, these T cells respond to
cross-reacting keratin antigens [5, 13]. Psoriatic plaque T-cells
being oligoclonal with few clones recognising antigens are
similar to streptococcal M-protein, namely, keratin-16 and
keratin-17 in the psoriatic plaques [5, 12]. Therefore, the T
cells in psoriatic lesionsmay be reacting to a group of antigens
or alternatively; they might be a proliferative response of
memory T cells, proliferating in response to cytokines in an
antigen-independent manner which exacerbate the disease
pathology [5].
Psoriasis has been classified as a Th1 disease since
cytokines of the Th1 pathway (IFN-𝛾, IL-2, and IL-12)
predominate in psoriatic plaques [4]. However, recent dis-
coveries suggest that Th17 is also a significant modulator in
the immunopathogenesis of psoriasis (Table 1). Th17-related
cytokines, including IL-17A, IL-17F, IL-21, and IL-22, are
overexpressed in psoriatic plaque [5, 14, 15]. IL-21 and IL-
22 induce keratinocyte hyperplasia while IL-17 synergises
with IFN-𝛾 and increases the synthesis of proinflamma-
tory cytokines (IL-6 and IL-8) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) by keratinocytes [5, 16].
BioMed Research International 3
Table 1: A summary of different subsets of T cells and the role of their respective cytokines in the pathogenesis of psoriasis. Figure adapted
and modified from [28].









Th1 IFN-𝛾 ∙ ∙ ∙




Th22 IL-22 ∙ ∙
FoxP3+ Treg IL-17 ∙ ∙ ∙
CD8+





Dermal IL-17 ∙ ∙ ∙
IL-22 ∙
TNF-𝛼 ∙ ∙
NK IL-17 ∙ ∙ ∙
IL-23 is produced by stimulated DCs, macrophages, and
other antigen-presenting cells [5]. Production of IL-23 ampli-
fies theTh17 cell responses and causes psoriatic lesions when
administered intradermally to mice [5, 15].
The presence of innate immune cells and their products
in psoriatic skin plaques suggests a role for innate immunity.
Cells of the innate immune system include macrophages,
natural killer- (NK-) T cells, and DCs. There is an increased
number of plasmacytoid and myeloid DCs in psoriatic
skin compared with nonlesional skin [5]. Plasmacytoid
DCs express TLR (Toll-like receptor) 9 and produce IFN-𝛼
when activated with the antimicrobial cathelicidin LL37
bound to self-DNA fragments released by injured cells in the
skin [5, 17]. Additionally, plasmacytoid DCs express TLR7
and TLR8 which also upregulate IFN-𝛼 production when
stimulated with self-RNA-LL37 complexes [18, 19]. IFN-𝛼 is a
key mediator for T-cell-dependent development of psoriasis
[19]. Self-RNA-LL37 complexes can also interact with TLR8
on myeloid DCs and promote their differentiation into
mature DCs with secretion of IL-12, IL-23, TNF-𝛼, and iNOS
(inducible nitric oxide synthase) [5]. Other cellular elements
of innate immunity are also involved in the development
of psoriasis. The psoriatic plaque contains high numbers
of macrophages which can secrete IL-6, IL-12, IL-23, and
TNF-𝛼 [5]. Keratinocytes are also capable resident antigen-
presenting cells (APCs) in the skin. They express TLRs and
when stimulated, they produce large amounts of cytokines
(e.g., TNF-𝛼, IL-6, and IL-18), chemotactic chemokines
(e.g., IL-8 and CCL20 (CC chemokine ligand 20)), and
antimicrobial peptides (e.g., 𝛽-defensin and LL37) [5, 20].
NK-T cells recognise glycolipid antigens presented by the
CD1d molecule and rapidly secrete IFN-𝛾 and IL-4, which
further exacerbates the inflammatory response leading to
the development of psoriatic plaques [21]. This antigen-
presenting molecule are overexpressed by keratinocytes in
psoriatic plaques [22]. Other elements of the innate immune
response (e.g., neutrophils and mast cells) are also involved
in the pathogenesis of psoriasis. However, their distinct roles
in the disease aetiology remain to be ascertained [5] and it is
generally accepted that both innate and acquired immunity
contribute to the pathogenesis of psoriasis (Figure 2).
4. Management and Treatment of Psoriasis
The management of psoriasis begins with patient education
[23]. Patients may reduce their disease relapses by learning
about environmental triggers. In addition, the use of an
emollient and a soap substitute can reduce skin irritation and
retain moisture, hence helping relieve the symptoms associ-
ated with psoriasis [23]. The first line of active treatments for
psoriasis involves the use of topical agents [23, 24]. There is
currently no evidence-based “therapeutic ladder” by which
to sequence topical treatments [24]. When topical therapy
fails, patients are referred to the dermatologist for escalated
treatment which often includes phototherapy, oral systemic
agents, and/or injectable biological therapies. In general, a
quarter of patients with psoriasis have moderate-to-severe
forms of the disease [25]. The efficacy of treatment for psori-
asis is commonly presented as PASI (Psoriasis Area Severity
Index) 50, PASI 75, or PASI 90 (i.e., the percentage of patients
who achieve a reduction in psoriasis severity in a particular
area following the use of topical agents in combination or
alone, when compared to their own baselines, that is, 50%,
75%, or 90% reduction in disease severity) [26]. In practice,
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Figure 2: Contribution of both acquired and innate immunity to the pathogenesis of psoriasis. Acquired immunity leads to a T-cell
activation and differentiation in response to different inflammatory signals while the innate immunity responds to a local tissue damage
and proinflammatory cytokines production which in combination with nucleic acids from dying keratinocytes trigger the activation of TLR
8 and TLR 9 inmyeloid DCs and plasmacytoid DCs, respectively.The interplay between the keratinocytes and immunemediators contributes
to the formation of a self-perpetuating loop. IL: interleukin; IFN: interferon; TGF: transforming growth factor; TNF: tissue necrosis factor;
pDC: plasmacytoid dendritic cell; mDC: myeloid dendritic cell; TLR: Toll-like receptor.
treatments of psoriasis are most commonly combined with
different agents to achieve synergistic therapy. Table 2 sum-
marises the recent research findings assessing the efficacy of
potential combinations with main focus on topical agents,
phototherapy, and systemic agents currently available [27].
4.1. Topical Agents. In a Cochrane review published in 2009
with treatment length of 6 weeks, corticosteroids, vitamin D
analogues, and tazarotene all performed better than placebo
in the treatment of chronic plaque psoriasis [29]. Vitamin
D analogues and corticosteroids showed the greatest efficacy
[29]. Corticosteroids bind to steroid receptors and alter gene
transcription, resulting in anti-inflammatory, immunosup-
pressive, and antiproliferative properties [30]. Low-potency
corticosteroids are used on delicate areas, including the face,
genitals, or flexures, often with shorter treatment courses
and with breaks in treatment [23, 30]. Prolonged exposure
to topical corticosteroids may lead to atrophy of the skin,
permanent striae, and telangiectasia [30, 31]. Vitamin D
analogues (e.g., calcitriol, calcipotriol, and tacalcitol) are
effective antipsoriatic agents but the precise mechanism is
still unknown. In vitro studies have shown that vitamin
D impedes keratinocyte proliferation and vitamin D
3
also
inhibits production of IL-2 and IL-6, blocks transcription of
IFN-𝛾 and GM-CSF mRNA, and inhibits cytotoxic T cells
and natural killer cell activity [32]. However, excessive use
can lead to hypercalcaemia. The probability of treatment
success doubles when combining vitamin D analogues with
topical corticosteroids as compared with the vitamin D
analogue monotherapy. As a result, the recommended first-
line induction treatment of plaque psoriasis is a combination
of a vitamin D analogue and a topical steroid [23, 24].
Other topical agents are commonly combined with top-
ical corticosteroids and vitamin D analogues when treating
psoriatic plaques. Salicylic acid is a topical keratolytic agent
used adjunctly for removing scales, and it acts by reducing
coherence between keratinocytes, increasing hydration, and
softening of the stratum corneum by decreasing the skin
pH [31]. However, systemic salicylic acid toxicity can occur
after long-term use over large skin areas [30, 31]. Retinoids,
another popular treatment agent for psoriasis, act on skin by
mediating cell differentiation and proliferation [30]. Systemic
retinoids are associated with several adverse effects including
teratogenicity, serum lipid elevations, mucocutaneous toxi-
city, skeletal changes, and hair loss [30]. The topical form,
Tazarotene, is formulated to avoid many of these systemic
side effects; however, it is still not recommended for pregnant
women [30]. Tazarotene is applied sparingly and over a
limited surface area with topical corticosteriods for resistant
plaques [30]. Coal tar and dithranol have been used for
many years but are no longer in modern practice since the
availability of systemic therapies [23].
4.2. Phototherapy. Ultraviolet (UV) light therapy induces T-
lymphocyte apoptosis in psoriatic lesions of the dermis and
epidermis [26]. Oral 8-methoxypsoralen-UV-A (PUVA) and
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Table 2: A summary of combination treatments for-mild-to severe psoriasis vulgaris. Results are tabulated from findings from a recent
systematic review and meta-analysis [27].
Combination treatment for psoriasis
Agents Outcomes
Topical vitamin D analogues and
corticosteroids
Patients had a 22% (95% CI: 12%–33%) increased likelihood of clearance than did
patients receiving vitamin D derivative monotherapy
Topical vitamin D analogues and UV-B
phototherapy
Patients had no statistically significant increase (11%; 95% CI: 2%–24%) in the
likelihood of clearance than did patients receiving UV-B monotherapy
Topical retinoids and vitamin D analogues Patients had a 33% (95% CI: 22%–44%) increased likelihood clearance than didpatients receiving topical retinoids monotherapy
Topical corticosteroids and salicylic acid Patients had no statistically significant increase (3%; 95% CI: 0%–7%) in thelikelihood of clearance than did patients receiving UV-B monotherapy
Topical corticosteroids and UV-B phototherapy Patients had no statistically significant increase (−6%; 95% CI: −24%–12%) in thelikelihood of clearance than did patients receiving UV-B monotherapy
Topical retinoids and corticosteroids Patients had a 19% (95% CI: 11%–27%) increased likelihood of clearance than didpatients receiving vitamin A derivative monotherapy
Topical retinoids and UV-B phototherapy Patients had a 21% (95% CI: 5%–36%) increased likelihood of clearance than didpatients receiving UV-B monotherapy
UV-B phototherapy and biological agents Patients had a 68% (95% CI: 51%–85%) increased likelihood of clearance than didpatients receiving alefacept monotherapy
UV-B phototherapy and methotrexate Patients had a 36% (95% CI: 10%–63%) increased likelihood clearance than didpatients receiving UV-B-methotrexate monotherapy
narrowband UVB (NB-UVB) are well-established and effec-
tive treatments for chronic plaque psoriasis. NB-UVB (wave-
length of 311–313 nm) compared to PUVA (320–400 nm) has
better antipsoriatic-to-erythemogenic ratio and removes the
need for protective eyewear and intake of psoralen tablets
[33]. In addition, NB-UVB is safe to administer during
pregnancy and in children [33]. PUVA has a response rate
of approximately 80% compared with 70% for NB-UVB
[24]. However, NB-UVB is preferred because of higher
convenience, except in case of very thick plaques [24]. The
risk of skin cancer is significantly higher with PUVA and
there is a theoretical risk of cancer with NB-UVB, however,
this is yet to be confirmed [24].
4.3. Systemic Treatments. Systemic treatments are often used
in combination with topical therapy and phototherapy for
patients with severe psoriasis. Currently available systemic
treatment options include oral agents and injectable biologi-
cal therapies.
The oral systemic agents for the treatment of pso-
riasis include methotrexate, cyclosporine, and acitretin.
Methotrexate decreases RNA andDNA synthesis in activated
T lymphocytes and keratinocytes in psoriatic lesions and
decreases the production of several cytokines [26]. The main
side effects frommethotrexate (gastrointestinal, hematologic,
and hepatotoxic toxicities) can be alleviated with folic acid
supplements [26]. Cyclosporine inhibits the translocation
of activated T lymphocytes and subsequent inflammatory
cytokine production [26]. Two major and frequent adverse
effects of cyclosporine include hypertension and nephrotox-
icity [26]. Cyclosporine is metabolised through cytochrome
P450 isoenzyme 3A4, and there is a safety concern with
potential drug-drug interactions systemic toxicities when
used in combination with isoenzymes 3A4 inhibitors (e.g.,
macrolides, grapefruit juice) andwith decreased effectiveness
when given with inducers (e.g., anticonvulsants, rifampin)
[26]. Acitretin, an oral retinoid, inhibits the induction of
helper T lymphocytes via IL-6 bymodulating gene expression
[26]. The effectiveness of acitretin is often dose dependent,
and it takes three to sixmonths to see themaximal response of
a particular dosage [26]. A significant proportion of patients
develop intolerable adverse effects, primarily mucosal and
skin effects, before the onset of therapeutic effects. Given its
teratogenicity, childbearing women wait for three years after
discontinuation before attempting conception [26].
Injectable biological therapies are emerging approaches
for the treatment of psoriasis by targeting molecules in the
inflammatory pathways. They are considered for patients
with severe psoriasis that are resistant to oral immuno-
suppressants and phototherapy. The two major therapeutic
classes of injectable biological therapies include anticytokine
therapies and T-cell-targeted therapies [5, 26]. The first class
consists of injectable immunoglobulins (Ig), infliximab, and
adalimumab, all of which target soluble and membrane-
bound TNF-𝛼 [5, 26]. Other anticytokine therapies include
Etanercept and Ustekinumab. Etanercept is a soluble dimeric
fusion protein that links the p75 TNF receptor to the Fc
portion of IgG [26]. Ustekinumab is the latest agent with high
binding affinity and specificity for the p40 subunits found
in both IL-12 and IL-23, preventing both cytokines from
activating their respective helper T cells [5, 26]. A second
therapeutic class of injectable the rapies include agents which
bind to T cells and prevent T-cells activation, including
alefacept and efalizumab [26]. While these biological agents
are not associated with the major organ toxicities seen with
traditional systemic therapies, they suppress the immune
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system and increase the risk of bacterial, fungal, and viral
infections, including tuberculosis [26]. Additionally, these
agents may aggravate existing or occult malignancies albeit
in less than 1% of patients, and long-term safety studies for
use of these agents are still not available [26]. Efalizumab
was withdrawn from the market by the manufacturer after
reports of four patients developing the deadly progressive
multifocal leukoencephalopathy (PML) [26]. In addition to a
high cost associatedwith the prescription of biological agents,
the current literature is limited, andmore randomised control
trials on larger cohort of patients are required to compare the
efficacies between different biological agents.
5. Experimental Models of Psoriasis
Psoriasis is not known to occur in animals; however, the
use of animal models has provided valuable knowledge
regarding the aetiology of this disease. A large number of
mouse models have been developed to emulate different
aspects of the human condition. The first models of psoriasis
were spontaneous mutations in mice which exhibited a
psoriasis-like phenotype. These included mice homozygous
for the asebia gene (Scd1ab/Scd1ab), chronic proliferative
dermatitis (𝑆ℎ𝑎𝑟𝑝𝑖𝑛cpdm/𝑆ℎ𝑎𝑟𝑝𝑖𝑛cpdm), and the flaky skin
(𝑇𝑡𝑐7fsn/𝑇𝑡𝑐7fsn) mutations [34]. These animals with many
histological features that mimic psoriasis and the driving
mechanisms of these phenotypes appear to be independent
of T cells which are known to be instrumental in this
disease development [34]. Transgenic mice models have
been employed to investigate the specific role of adhe-
sion molecules, cytokines, transcription factors, and other
mediators in the psoriasis [34]. Epidermal overexpression
of molecules of interest under the control of promoters
acting in basal (e.g., keratin 14) or suprabasal keratinocytes
(e.g., involucrin or keratin 10) provides information about
specific epidermal functions [34]. These latter models, how-
ever, may lack the inflammatory component of the disease
[35]. Deleting proteins within the epidermis including the
inhibitor of nuclear factor- (NF-) 𝜅B-kinase 2 (IKK2), signal
transducer and activator of transcription 3 (Stat3) has pro-
vided information about the role of signal transduction in
psoriasiform skin inflammation [34]. The most widely used
“mice” models are xenotransplantations where a skin biopsy
from a patient or produced in vitro is transplanted in mice
from spontaneously mutated or genetically modified mice
[34, 35]. The use of athymic nude mice and severe com-
bined immunodeficient mice serve to avoid graft rejection
but the former mice develop new histological changes not
seen in psoriasis while the latter mice continue to manifest
rejection of the xenogeneic tissue due to presence of NK
cells [35]. A new model has recently emerged where mice
with spontaneous expression of AGR129 have immature NK
cells and a lack of T and B cells resulting in the develop-
ment of psoriatic plaques which are comparable to patient
biopsies and a reduction in graft rejection [35]. Additionally,
an imiquimod-induced dermatitis mouse model has been
developed which leads to psoriasis-like dermatitis [36]. This
simple and reproducible model requires the application of
topical TLR7-agonist cream over the back skin resulting in
both skin inflammation and epidermal hyperplasia. Although
the model is widely used, further studies are still required to
determine if the inflammation observed in the mouse skin
is mediated by similar pathways observed in patients with
psoriasis. Ideally, the most appropriate animal model must
be easily reproducible, inexpensive and sufficiently mirror
human psoriasis [34, 35]. Xenotransplantation remains an
expensive and tedious model and no current models fulfil all
the features of human disease, hence necessitating the use of
different models depending on the specific research question
[34].
Commonly used in vitro models of psoriasis involve the
growth of human epidermal keratinocytes at an air-liquid
interface resulting in the differentiation and stratification
of the epidermis, hence mimicking the morphology of
normal stratified squamous epidermis [37]. The epidermal
keratinocytes can be obtained from individuals with psoriasis
or from normal individuals and can be treated with a variety
of cytokines and/or growth factors to result in psoriatic
phenotypes in this reconstituted human epidermal culture
model of psoriasis [37].The organotypicmodel exhibitsmany
features of human psoriasis including the upregulation of
chemokines, induction of hyperproliferativion, upregulation
of S100 family members, and activation of phosphorylated
signal transducer and activator of transcription (pStat3), one
of the major signal transducers in psoriatic epidermis [37].
However, this in vitromodel lacks the presence of leukocytes
and blood vessels which limits the usefulness of the model.
Nonetheless, it can be useful for studying many aspects of the
psoriatic epidermis, including keratinocytes differentiation
and response to treatment stimuli [37].
6. Current Research in Psoriasis
Themost recent laboratory research on psoriasis has focused
on the identification of novel T-cell subsets involved in
the pathogenesis of psoriasis including Gamma delta- (𝛾𝛿-)
T cells, V𝛾9V𝛿2-T-cells, Th22 cells, and Tregs (Table 1).
Gamma delta- (𝛾𝛿-) T cells belong to a subpopulation of
T cells which are increased in psoriatic lesions of different
patients [38]. These 𝛾𝛿-T cells are present in the dermis
and express IL-23 receptor, CCR6, and transcriptional fac-
tor ROR𝛾t and produce IL-17 upon Il-23 stimulation [38].
The importance of these T-cell subsets has been demon-
strated with disease severity being significantly reduced in
T-cell receptor 𝛿-deficient (TCRd−/−) mice using a com-
bined IL-23-Imiquimod-induced psoriasis model [38, 39].
Another T-cell subset recently identified in the human dis-
ease is the V𝛾9V𝛿2-T-cell subset which expresses cutaneous
lymphocyte-associated antigen and is increased in lesions
from psoriasis patients and is decreased in peripheral blood
[40]. Distinct population of memory T cells, called the Th22
cells, have also been characterised in psoriatic disease. These
cells produce only IL-22 and are present in the circulation
of psoriatic patients and psoriatic plaques along with Th1
and Th17 cells [28, 41, 42]. These findings suggest that Th22
cells contribute to disease development by creating a chronic
inflammatory environment for the maintenance of psoriatic
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plaques [28, 43]. Lastly, a subset of Tregs has been identified
to play a role in psoriasis. Tregs include T lymphocytes
that suppress autoimmune responses and excessive immune
responses to foreign antigens [28]. However, psoriatic Tregs
isolated from lesional psoriatic skin and peripheral blood
of psoriatic patients have been found to be functionally
deficient in suppressing effector T-cell responses in either
alloantigen-specific or polyclonal TCR stimulation assays [28,
44]. The possible mechanism for the decrease in suppression
is partially due to the proinflammatory cytokines produced
in the psoriasis lesions which inhibit Treg promotion of the
development of psoriatic lesions [28]. Interestingly, Tregs dif-
ferentiate into IL-17-producing cells under proinflammatory
stimulation [45]. Specifically, the CD4+CD25high Foxp3+ cells
aremore prone to conversion in patients with severe psoriasis
suggesting that they play a role in the disease [28, 45]. Given
T-cells, major role in psoriasis, the subsets of T cells are
promising therapeutic candidate for the development of new
therapies for psoriatic patients. Current research is focused
on better understanding the precise function of these specific
T-cell subsets in psoriasis with hope that it may be possible
to identify specific targets for future development of drug
therapies.
The most recent clinical-based research for psoriasis
has focused on developing new therapeutics with numerous
phase II clinical trials testing different injectable biological
agents involved in the pathogenic cascade of psoriasis. Drugs
under investigation include those targeting IL-17, IL-20, IL-
22, IL-23, and IL-23p19 cytokines [46]. Therapies directed
against key ligands involved inT-cell activation and signalling
offer an alternative means to manipulation of the immune
function and alteration of the disease activity in patients
with psoriasis. Full activation of T cells is dependent on
secondary binding of ligand B7 (APC bound) to CD28
(T-cell bound), and agents which alter this activation are
also currently being investigated in phase II clinical trials
including Abatacept and Siplizumab [47]. Abatacept is a
fusion protein that binds to the B7 protein and consequently
inhibits T-cell activation [47]. A further costimulatory signal
between APC and T-cell binding is observed between CD2
(on APC) and LFA3 (on T cell) [47]. CD2 also facilitates
the interaction between activated T cells and NK cells [47].
Themonoclonal antibody Siplizumab binds CD2 and further
inhibits T-cell activation [47]. Other pathways of interest
in the development of therapies for treatment of psoriasis
include the regulation of activated T-cells, migration from
the peripheral tissue into the lymph node. This process is
regulated by sphingosine 1-phosphate (S1P) receptor agonists
[47]. S1P1 agonist is currently being tested in the phase II
clinical trials in psoriatic patients [47]. In addition, clinical
trials are also focused on using small molecules which target
known signalling pathways involved in psoriasis including
Janus kinase-signal transducer and activators of transcription
(JAK-STAT), protein kinase C (PKC), andMitogen-Activated
Protein Kinase (MAPK) pathways [47]. A variety of small
molecules currently in phase II clinical trials are targeting
these pathways, and they may provide further options in the
management of psoriasis [47].
7. Conclusion
Psoriasis is now accepted as a chronic inflammatory skin
condition with a high disease burden. The last two decades
have seen further understanding of the pathogenesis that has
culminated in the revolution in the management of psoriasis
with the development of targeted biological treatments.
Problems still exist in relation to undesirable suppression of
the rest of the immune pathways. Further appreciation of the
immunology that underlies psoriasis will hopefully translate
to improved treatments that target specific anti-inflammatory
pathways directly related to disease pathogenesis while pre-
serving the integrity of the host immune system.
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